However, current guidelines or options of management of CRS are based on data of CD19 CAR and risk assessment of CRS occurrence of different diseases (ALL, lymphoma, or MM) use the same standard or method (5, 15–18). Here, CD19 is linked to acute lymphoblastic leukemia.